Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06033196 · ClinicalTrials.gov registry record · Phase 2
Tocilizumab in Lung Transplantation
A Phase 2 study of Lung Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT06033196: Recruiting Phase 2 study of Lung Transplant, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT06033196 is a Phase 2 study of Lung Transplant that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 350 participants, below the 1,253-participant average among 15 other Lung Transplant trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06033196, a Phase 2 study of Lung Transplant, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids). The primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance immunosuppression plus placebo (saline) as defined by a composite endpoint of a) CLAD, b) listed for re-transplantation, and c) death
Primary Outcome
1. The development of Chronic Lung Allograft Dysfunction (CLAD) * The development of any form of CLAD will be defined according to the standard 2019 The International Society for Heart and Lung Transplantation (ISHLT) criteria. 2. Listed for re-transplantation * Re-transplantation defined as the subject has been formally registered on the United Network for Organ Sharing (UNOS) waiting list to undergo a second lung transplant surgery 3. Death * Primary analysis will be conducted acco
Conditions Studied
Interventions
- DRUG Tocilizumab
- DRUG Placebo for Tocilizumab
Study Locations (20)
Texas
- University of Texas Southwestern (Site #: 71187) - Dallas
- Houston Methodist Hospital (Site #: 71120) - Houston
- University of Texas Health Science at San Antonio (Site #: 71198) - San Antonio
California
- Cedars Sinai Medical Center (Site #: 71146) - Beverly Hills
- David Geffen School of Medicine at UCLA (Site #: 71123) - Los Angeles
Massachusetts
- Massachusetts General Hospital (Site #: 71107) - Boston
- Boston Children's Hospital and Harvard Medical School (Site #: 71001) - Boston
Missouri
- Barnes Jewish Hospital/ Washington University SOM (Site #: 71191) - St Louis
- St. Louis Children's Hospital of Washington University (Site #: 71006) - St Louis
Ohio
- Cleveland Clinic (Site #: 71101) - Cleveland
- Ohio State University Medical Center (Site #: 71196) - Columbus
Arizona
- St. Joseph's Hospital and Medical Center (Site #: 71192) - Phoenix
Florida
- University of Florida Shands Hospital (Site #: 71131) - Gainesville
Georgia
- Emory University (Site #: 71103) - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-02-13 |
| Est. Completion | 2029-01-08 |
| Phase | Phase 2 |
What NCT06033196 shows while recruiting
NCT06033196 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 1,253-participant average among 15 other Lung Transplant trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Lung Transplant appearing as the primary indexed condition, and to 2 interventions - of which Tocilizumab is the first listed.
NCT06033196 names 20 study sites across 14 states, led by Texas, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06033196 about?
NCT06033196 is a clinical study titled "Tocilizumab in Lung Transplantation". This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycop...
What is the current status of trial NCT06033196?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2024-02-13. Estimated completion is 2029-01-08.
What conditions does trial NCT06033196 study?
This clinical trial studies the following conditions: Lung Transplant.
What interventions are being tested in trial NCT06033196?
The interventions under investigation include: Tocilizumab (DRUG), Placebo for Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT06033196?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06033196 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06033196's enrollment target sits among peer trials
350 3rd of 15 higher than 13 of 15 other Lung Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
RECRUITING · Phase 2
-
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
RECRUITING
-
Pre-transplant Health Coaching to Improve Patient-Reported Outcomes in Lung Transplant Candidates
RECRUITING · NA
-
Planned Semi-Elective Lung Tx Study
RECRUITING · NA
-
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
RECRUITING
-
A Study of Latin Dance for Post- Lung Transplant
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI